Vor Biopharma (VOR) Stock Research

Over a week ago

Vor Bio announces China NMPA approval for telitacicept

Jun 8, 9:04 AM

Vor Bio price target raised by $3 at Wedbush, here's why

May 14, 8:00 AM

Vor Bio files to sell 5.34M shares of common stock for holders

Apr 27, 4:13 PM

Vor Bio price target lowered by $1 at H.C. Wainwright, here's why

Apr 15, 6:03 AM

Vor Bio price target raised by $6 at Wedbush, here's why

Mar 31, 7:54 AM

Vor Bio price target lowered by $15 at Stifel, here's why

Mar 30, 2:28 PM

Vor Bio doses first patient in UPSTREAM SjD study

Mar 30, 8:05 AM

Vor Bio initiated with bullish view at Jefferies, here's why

Mar 29, 7:28 PM

Vor Bio to sell 5.338M shares at $14.05 in private placement

Mar 27, 8:23 AM

Vor Bio initiated with bullish view at Wells Fargo, here's why

Mar 19, 5:55 AM

Galapagos CHRO Annelies Missotten to step down, Tania Philipp to succeed

Mar 5, 4:39 PM

Vor Bio files to sell 13.88M shares of common stock for holders

Jan 29, 4:16 PM

Vor Bio initiated with bullish view at Citi, here's why

Jan 9, 6:13 AM

Vor Bio price target lowered by $18 at Baird, here's why

Dec 23, 6:59 AM

Vor Bio price target lowered by $3 at JPMorgan, here's why

Dec 19, 6:56 AM

Vor Bio initiated with bullish view at TD Cowen, here's why

Dec 17, 5:38 AM

Vor Bio prices 13.88M shares at $10.81 in private placement

Dec 15, 8:04 AM

Vor Bio initiated with bullish view at JPMorgan, here's why

Dec 9, 4:59 AM

Vor Bio assumed with a Neutral at Wedbush

Nov 25, 8:35 AM

Vor Bio price target lowered by $23 at H.C. Wainwright, here's why

Nov 14, 6:12 AM

Vor Bio 10M share Spot Secondary priced at $10.00

Nov 10, 11:30 PM

Vor Bio $100M Spot Secondary; price range $10.00-$12.00

Nov 10, 4:18 PM

Vor Bio announces $100M common stock offering

Nov 10, 4:07 PM

Vor Bio achieves primary endpoint in Stage A of Phase 3 study of telitacicept

Nov 9, 1:17 PM

Vor Bio appoints Sokolove as Chief Medical Officer

Nov 3, 8:05 AM